Worg is a clinical stage biopharmaceutical company developing new treatments for allergic and autoimmune diseases, with the ambition to extend its portfolio to other therapeutic areas of high unmet medical needs and considerable commercial potential.

With the headquarter in Shanghai and a subsidiary company in Basel, Worg is at the hearts of European and Chinese pharmaceutical industry. Founded in 2018, Worg is led by international executive members from China, the United States and Europe who have extensive experience in life science executive, pharmaceutical development, regulatory affairs, and commercialization.  

Worg is building a pipeline for immunotherapy of allergy, autoimmune diseases and other disorders through internal development and external partnering by flexible business models.